Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Elixir licenses rights to BMS's growth hormone stimulant

Executive Summary

Seeking to become a fully integrated biopharmaceutical company, Elixir, which develops drugs for diseases related to aging, has licensed exclusive worldwide development and commercialization rights to Bristol-Myers Squibb's ghrelin agonist BMS-604992 (later called, EX1314, it stimulates appetite, gastric motility, and the release of growth hormone). and five related compounds to treat metabolic disorders.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies